SCHEMBL5475464

SCHEMBL5475464

COc1cccc(-c2cnc(Nc3ccc(-n4ccnc4)nc3)o2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VCP P55072 2/20 0.61
IMPDH2 P12268 8/20 0.55
KDR P35968 7/20 0.53
FLT1 P17948 6/20 0.53
FLT4 P35916 6/20 0.53
LMNA P02545 2/20 0.52
CYP1A2 P05177 2/20 0.52
CYP3A4 P08684 2/20 0.52
CYP2D6 P10635 2/20 0.52
MAPT P10636 2/20 0.52
CYP2C19 P33261 2/20 0.52
TDP1 Q9NUW8 2/20 0.52
TP53 P04637 1/20 0.52
MAPK1 P28482 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48
CYP2C9 P11712 1/20 0.48
HPGD P15428 1/20 0.48
HSD17B10 Q99714 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5472883 0.81 VCP (0.62) VCPIMPDH2KDRFLT1FLT4
SCHEMBL5465207 0.80 VCP (0.61) VCPIMPDH2KDRFLT1FLT4
SCHEMBL16349128 0.80 VCP (0.60) VCPIMPDH2KDRFLT1FLT4
SCHEMBL5477528 0.77 VCP (0.80) VCPIMPDH2KDRFLT1FLT4
SCHEMBL5465359 0.77 VCP (0.65) VCPIMPDH2KDRFLT1FLT4
SCHEMBL5477700 0.76 KDR (0.76) VCPIMPDH2KDRFLT1FLT4
SCHEMBL5470454 0.73 VCP (0.69) VCPIMPDH2KDRFLT1FLT4
SCHEMBL5469457 0.73 VCP (0.68) VCPIMPDH2KDRFLT1FLT4
SCHEMBL5469734 0.73 VCP (0.68) VCPIMPDH2KDRFLT1FLT4
SCHEMBL15121122 0.72 IMPDH2 (0.64) VCPIMPDH2KDRFLT1FLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070142437-A1 CHEMICAL COMPOUNDS BROWN MATTHEW L 2007-06-21 US claimed
US-20050288515-A1 Chemical compounds SMITHLINE BEECHAM CORPORATION 2005-12-29 US claimed
US-20070142437-A1 CHEMICAL COMPOUNDS BROWN MATTHEW L 2007-06-21 US disclosed
US-20070142437-A1 CHEMICAL COMPOUNDS BROWN MATTHEW L 2007-06-21 US disclosed
US-20070142437-A1 CHEMICAL COMPOUNDS BROWN MATTHEW L 2007-06-21 US disclosed
US-7189712-B2 1,3-Oxazole compounds for the treatment of cancer SMITHKLINE BEECHAM CORPORATION (US) 2007-03-13 US disclosed
US-7189712-B2 1,3-Oxazole compounds for the treatment of cancer SMITHKLINE BEECHAM CORPORATION (US) 2007-03-13 US disclosed
US-7189712-B2 1,3-Oxazole compounds for the treatment of cancer SMITHKLINE BEECHAM CORPORATION (US) 2007-03-13 US disclosed
US-20050288515-A1 Chemical compounds SMITHLINE BEECHAM CORPORATION 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142437-A1 CHEMICAL COMPOUNDS CDK4, CDK2, CDK3 VCP 3873/4885IMPDH2 2297/4885KDR 33/4885
US-20050288515-A1 Chemical compounds CDK4, CDK2, CDK3 VCP 3873/4885IMPDH2 2297/4885KDR 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.